Decoding NVO Stock – Market Analysis Summary

By Blake Campbell • Thursday, July 24 10:05 • Permanent Link

Large-cap Health Care company Novo Nordisk A/S has moved 1.6% so far today on a volume of 1,467,566, compared to its average of 9,494,050. In contrast, the S&P 500 index moved 0.0%.

Novo Nordisk A/S trades -18.48% away from its average analyst target price of $87.3 per share. The 11 analysts following the stock have set target prices ranging from $61.819054 to $112.34373, and on average have given Novo Nordisk A/S a rating of buy.

If you are considering an investment in NVO, you'll want to know the following:

Novo Nordisk A/S's current price is -44.4% below its Graham number of $127.92, which implies the stock has a margin of safety
Novo Nordisk A/S has moved -45.2% over the last year, and the S&P 500 logged a change of 17.8%
Based on its trailing earnings per share of 3.68, Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 19.3 while the S&P 500 average is 29.3
NVO has a forward P/E ratio of 17.5 based on its forward 12 month price to earnings (EPS) of $4.07 per share
Its Price to Book (P/B) ratio is 2.28 compared to its sector average of 3.19
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Based in Bagsvaerd, the company has 77,406 full time employees and a market cap of $314.39 Billion. Novo Nordisk A/S currently returns an annual dividend yield of 16.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.